Citation:Rajeswaran A, Trojan A, Burnand B, Giannelli M 2008

Citation

Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008 Jan;59(1):1-11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17720276.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Rajeswaran A, Trojan A, Burnand B, Giannelli M 2008	What is the optimal systemic therapy for stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Rajeswaran A, Trojan A, Burnand B, Giannelli M 2008 2	What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Rajeswaran A, Trojan A, Burnand B, Giannelli M 2008 3	Is carboplatin based chemotherapy as effective as cisplatin based chemotherapy for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Rajeswaran A, Trojan A, Burnand B, Giannelli M 2008 4	Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Rajeswaran A, Trojan A, Burnand B, Giannelli M 2008 5	Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Rajeswaran A, Trojan A, Burnand B, Giannelli M 2008 6	Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Rajeswaran A, Trojan A, Burnand B, Giannelli M 2008 7	What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:Is carboplatin based chemotherapy as effective as cisplatin based chemotherapy for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. Are non-platinum doublet chemotherapy regimens as effective as platinum doublet regimens for treatment of stage IV inoperable NSCLC?
2. What is the optimal systemic therapy for stage IV inoperable NSCLC?